COPD Devices Market Scope and Analysis by 2030
COPD Devices Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 8,849.16 Million |
| Market Size by 2030 | US$ 12,877.43 Million |
| Global CAGR (2022 - 2030) | 4.8% |
| Historical Data | 2020-2022 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Industry Developments and Future Opportunities:
Various plans by key players operating in the COPD devices market are listed below:
- In April 2022, GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) in India. It is the first single-inhaler triple therapy (SITT) for COPD patients in a once-daily regime. The product was also approved by the Drugs Controller General of India (DCGI) for consumption of Trelegy Ellipta as a maintenance treatment for preventing and relieving symptoms related to COPD in patients aged 18 and above.
Competitive Landscape and Key Companies:
A few of the prominent players operating in the COPD devices market are AstraZeneca PLC, Beximco Pharmaceuticals Ltd, Getinge AB, Boehringer Ingelheim, GSK Plc, Medtronic PLC, Nephron Pharmaceuticals, Novartis AG, Sunovion Pharmaceuticals Inc, and Teva Pharmaceuticals. These companies focus on geographic expansions and new product launches to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.
Get Free Sample For